Pharmacotherapeutic approaches to the prevention of Alzheimer's disease

Hebert, 2003, Alzheimer disease in the US population: Prevalence estimates using the 2000 census, Arch Neurol, 60, 1119, 10.1001/archneur.60.8.1119 Brookmeyer, 1998, Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset, Am J Public Health, 88, 1337, 10.2105/AJPH.88.9.1337 Cummings, 2002, Alzheimer disease, JAMA, 287, 2335, 10.1001/jama.287.18.2335 Schulz, 2003, End-of-life care and the effects of bereavement on family caregivers of persons with dementia, N Engl J Med, 349, 1936, 10.1056/NEJMsa035373 2004, Authors guide Larson, 1996, Prevention of Alzheimer disease: A perspective based on successes in the prevention of other chronic diseases, Alzheimer Dis Assoc Disord, 10, 9, 10.1097/00002093-199601031-00003 Launer, 1997, Histamine H2 blocking drugs and the risk for Alzheimer's disease: The Rotterdam Study, Neurobiol Aging, 18, 257, 10.1016/S0197-4580(97)00010-9 Zandi, 2002, Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study, Neurology, 59, 880, 10.1212/WNL.59.6.880 Zandi, 2002, Is pharmacological prevention of Alzheimer's a realistic goal?, Expert Opin Pharmacother, 3, 365, 10.1517/14656566.3.4.365 Behl, 1997, Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease, Cell Tissue Res, 290, 471, 10.1007/s004410050955 Christen, 2000, Oxidative stress and Alzheimer disease, Am J Clin Nutr, 71, 621S, 10.1093/ajcn/71.2.621s Fawcett, 2002, Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants, Brain Res, 950, 10, 10.1016/S0006-8993(02)02981-5 Naiki, 1998, Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro, Biochemistry, 37, 17882, 10.1021/bi980550y Engelhart, 2002, Dietary intake of antioxidants and risk of Alzheimer disease, JAMA, 287, 3223, 10.1001/jama.287.24.3223 Morris, 1998, Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease, Alzheimer Dis Assoc Disord, 12, 121, 10.1097/00002093-199809000-00001 Masaki, 2000, Association of vitamin E and C supplement use with cognitive function and dementia in elderly men, Neurology, 54, 1265, 10.1212/WNL.54.6.1265 Zandi, 2004, Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study, Arch Neurol, 61, 82, 10.1001/archneur.61.1.82 Morris, 2002, Vitamin E and cognitive decline in older persons, Arch Neurol, 59, 1125, 10.1001/archneur.59.7.1125 Morris, 2002, Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study, JAMA, 287, 3230, 10.1001/jama.287.24.3230 Luchsinger, 2003, Antioxidant vitamin intake and risk of Alzheimer disease, Arch Neurol, 60, 203, 10.1001/archneur.60.2.203 White, 2001, Correlates of serum alpha- and gamma-tocopherol in the Women's Health Initiative, Ann Epidemiol, 11, 136, 10.1016/S1047-2797(00)00189-7 Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study, N Engl J Med, 336, 1216, 10.1056/NEJM199704243361704 Johnson, 2002, Vitamin nutrition in older adults, Clin Geriatr Med, 18, 773, 10.1016/S0749-0690(02)00048-4 Sloane, 1998, Advances in the treatment of Alzheimer's disease, Am Fam Phys, 58, 1577 Sloane, 1998, Advances in the treatment of Alzheimer's disease, Am Fam Phys, 58, 1589 Kawano, 2003, Effects of transderreal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state, Int J Clin Pharmacol Ther, 41, 346, 10.5414/CPP41346 Marin, 2003, Estradiol prevents amyloid-beta peptide-induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor, Neuroscience, 121, 917, 10.1016/S0306-4522(03)00464-0 Shah, 2003, Estrogen-induced changes in the microtubular system correlate with a decreased susceptibility of aging neurons to beta amyloid neurotoxicity, Mol Cell Neurosci, 24, 503, 10.1016/S1044-7431(03)00166-0 Wise, 2002, Estrogens and neuroprotection, Trends Endocrinol Metab, 13, 229, 10.1016/S1043-2760(02)00611-2 Czlonkowska, 2003, Influence of estrogens on neurodegenerative processes, Med Sci Monit, 9, RA247 Cholerton, 2002, Estrogen and Alzheimer's disease: The story so far, Drugs Aging, 19, 405, 10.2165/00002512-200219060-00002 Rhodin, 2003, In vivo cerebrovascular actions of amyloid beta-peptides and the protective effect of conjugated estrogens, J Alzheimers Dis, 5, 275, 10.3233/JAD-2003-5403 Baker, 2003, 17Beta-estradiol reduces plasma Abeta40 for HRT-naive postmenopausal women with Alzheimer disease: A preliminary study, Am J Geriatr Psychiatry, 11, 239 Baldereschi, 1998, Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging, Neurology, 50, 996, 10.1212/WNL.50.4.996 Kawas, 1998, A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging, Neurology, 51, 654 Kawas, 1997, Neurology, 48, 1517, 10.1212/WNL.48.6.1517 Tang, 1996, Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet, 348, 429, 10.1016/S0140-6736(96)03356-9 LeBlanc, 2001, Hormone replacement therapy and cognition: Systematic review and meta-analysis, JAMA, 285, 1489, 10.1001/jama.285.11.1489 Thal, 2003, Estrogen levels do not correlate with improvement in cognition, Arch Neurol, 60, 209, 10.1001/archneur.60.2.209 Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study, JAMA, 284, 2597 Mulnard, 2000, JAMA, 283, 1007, 10.1001/jama.283.8.1007 Shumaker, 2003, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial, JAMA, 289, 2651, 10.1001/jama.289.20.2651 Rapp, 2003, Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial, JAMA, 289, 2663, 10.1001/jama.289.20.2663 Perry, 2002, Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: Effect on lipids, coagulation factors, haematology and biochemistry, Maturitas, 42, 157, 10.1016/S0378-5122(02)00039-7 Luyer, 2001, Prospective randomized study of effects of unopposed estrogen replacement therapy on mariners of coagulation and inflammation in postmenopausal women, J Clin Endocrinol Metab, 86, 3629, 10.1210/jc.86.8.3629 Yaffe, 1998, Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia, JAMA, 279, 688, 10.1001/jama.279.9.688 Norbury, 2003, The neuroprotective effects of estrogen on the aging brain, Exp Gerontol, 38, 109, 10.1016/S0531-5565(02)00166-3 Maki, 2003, The menopause and HILT. HILT and cognitive decline, Best Pract Res Clin Endocrinol Metab, 17, 105, 10.1016/S1521-690X(02)00082-9 McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies, Neurology, 47, 425, 10.1212/WNL.47.2.425 Landi, 2003, Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients, Am J Geriatr Psychiatry, 11, 179, 10.1176/appi.ajgp.11.2.179 Weggen, 2001, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclo-oxygenase activity, Nature, 414, 212, 10.1038/35102591 Weggen, 2003, Abeta42-1owering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain, J Biol Chem, 278, 30748, 10.1074/jbc.M304824200 Takahashi, 2003, Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation, J Biol Chem, 278, 18664, 10.1074/jbc.M301619200 Broe, 2000, Anti-inflammatory drugs protect against Alzheimer disease at low doses, Arch Neurol, 57, 1586, 10.1001/archneur.57.11.1586 in t' Veld, 2001, Non-steroidal antiinflammatory drugs and the risk of Alzheimer's disease, N Engl J Med, 345, 1515, 10.1056/NEJMoa010178 Tabet, 2003, Ibuprofen for Alzheimer's disease, Cochrane Database Syst Rev, 2, CD004031 Etminan, 2003, Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies, BMJ, 327, 128, 10.1136/bmj.327.7407.128 Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial, JAMA, 289, 2819, 10.1001/jama.289.21.2819 Catella-Lawson, 2001, Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N Engl J Med, 345, 1809, 10.1056/NEJMoa003199 Aisen, 2002, Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease, J Pain Symptom Manage, 23, S35, 10.1016/S0885-3924(02)00374-3 Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study, BMJ, 322, 1447, 10.1136/bmj.322.7300.1447 Vagnucci, 2003, Alzheimer's disease and angiogenesis, Lancet, 361, 605, 10.1016/S0140-6736(03)12521-4 Suo, 1997, Superoxide free radical and intracellular calcium mediate A beta(1–42) induced endothelial toxicity, Brain Res, 762, 144, 10.1016/S0006-8993(97)00383-1 Austen, 2002, Relation between cholesterol levels, statins and Alzheimer's disease in the human population, J Nutr Health Aging, 6, 377 Kivipelto, 2001, Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study, Neurology, 56, 1683, 10.1212/WNL.56.12.1683 Chorsky, 2001, Alzheimer's disease: A review concerning immune response and microischemia, Med Hypotheses, 56, 124, 10.1054/mehy.2000.1148 Malouf, 2003, Folic acid with or without vitamin B12 for cognition and dementia, Cochrane Database Syst Rev, CD004514 Levey, 2000, Molecules of the brain, Hosp Pract (Off Ed), 35, 41, 10.3810/hp.2000.02.186 Levey, 2000, Molecules of the brain, Hosp Pract (Off Ed), 35, 51, 10.3810/hp.2000.02.186 Rubinsztein, 2000, Apolipoprotein E genetic variation and Alzheimer's disease. A meta-analysis, Dement Geriatr Cogn Disord, 11, 238 Rubinsztein, 1999, Dement Geriatr Cogn Disord, 199, 10.1159/000017120 Tapiola, 2000, Relationship between apoE genotype and CSF beta-amyloid (1–42) and tau in patients with probable and definite Alzheimer's disease, Neurobiol Aging, 21, 735, 10.1016/S0197-4580(00)00164-0 Michikawa, 2003, The role of cholesterol in pathogenesis of Alzheimer's disease: Dual metabolic interaction between amyloid beta-protein and cholesterol, Mol Neurobiol, 27, 1, 10.1385/MN:27:1:1 Kivipelto, 2002, Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease, Ann Intern Med, 137, 149, 10.7326/0003-4819-137-3-200208060-00006 Haley, 2000, Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?, Arch Neurol, 57, 1410, 10.1001/archneur.57.10.1410 Vega, 2003, Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease, Arch Neurol, 60, 510, 10.1001/archneur.60.4.510 Burns, 2002, Cholesterol in Alzheimer's disease and tauopathy, Ann N Y Acad Sci, 977, 367, 10.1111/j.1749-6632.2002.tb04839.x Naidu, 2002, Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins, Brain Res, 958, 100, 10.1016/S0006-8993(02)03480-7 Stalenhoef, 1993, Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study, J Intern Med, 234, 77, 10.1111/j.1365-2796.1993.tb00708.x Davidson, 1997, Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia, Am J Cardiol, 79, 1475, 10.1016/S0002-9149(97)00174-4 Wolozin, 2000, Decreased prevalence of Alzheimer disease associated with 3-hydroxy- 3-methyglutaryl coenzyme A reductase inhibitors, Arch Neurol, 57, 1439, 10.1001/archneur.57.10.1439 Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X Fassbender, 2001, Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo, 98, 5856 Linton, 2003, A practical approach to risk assessment to prevent coronary artery disease and its complications, Am J Cardiol, 92, 19i, 10.1016/S0002-9149(03)00505-8 Morgan, 2003, Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines, Geriatrics, 58, 33 Morgan, 2003, Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines, Geriatrics, 58, 41 Rigaud, 2000, Cerebral complications of hypertension, J Hum Hypertens, 14, 605, 10.1038/sj.jhh.1001118 Birkenhager, 2001, Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension, Arch Intern Med, 161, 152, 10.1001/archinte.161.2.152 in't Veld, 2001, Antihypertensive drugs and incidence of dementia: The Rotterdam Study, Neurobiol Aging, 22, 407, 10.1016/S0197-4580(00)00241-4 Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch Intern Med, 163, 1069, 10.1001/archinte.163.9.1069 Forette, 2002, The prevention of dementia with antihypertensive treatment: New evidence from the Systolic Hypertension in Europe (Syst-Eur) study, Arch Intern Med, 162, 2046, 10.1001/archinte.162.18.2046 Prince, 1996, Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults, BMJ, 312, 801, 10.1136/bmj.312.7034.801 Weber, 2003, Treating hypertension in the elderly: Protagonist viewpoint, Am J Geriatr Cardiol, 12, 361, 10.1111/j.1076-7460.2003.02915.x Snowdon, 1997, Brain infarction and the clinical expression of Alzheimer disease. The Nun Study, JAMA, 277, 813, 10.1001/jama.1997.03540340047031 Scherr, 1992, Light to moderate alcohol consumption and mortality in the elderly, J Am Geriatr Soc, 40, 651, 10.1111/j.1532-5415.1992.tb01954.x Ajani, 2000, Alcohol consumption and risk of coronary heart disease by diabetes status, Circulation, 102, 500, 10.1161/01.CIR.102.5.500 Solomon, 2000, Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus, Circulation, 102, 494, 10.1161/01.CIR.102.5.494 Stampfer, 2000, Primary prevention of coronary heart disease in women through diet and lifestyle, N Engl J Med, 343, 16, 10.1056/NEJM200007063430103 Mukamal, 2003, Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men, N Engl J Med, 348, 109, 10.1056/NEJMoa022095 Huang, 2002, Alcohol consumption and incidence of dementia in a community sample aged 75 years and older, J Clin Epidemiol, 55, 959, 10.1016/S0895-4356(02)00462-6 Ruitenberg, 2002, Alcohol consumption and risk of dementia: The Rotterdam Study, Lancet, 359, 281, 10.1016/S0140-6736(02)07493-7 Luchsinger, 2004, Alcohol intake and risk of dementia, J Am Geriatr Soc, 52, 540, 10.1111/j.1532-5415.2004.52159.x Commenges, 2000, Intake of flavonoids and risk of dementia, Eur J Epidemiol, 16, 357, 10.1023/A:1007614613771 Dajas, 2003, Cell culture protection and in vivo neuroprotective capacity of flavonoids, Neurotox Res, 5, 425, 10.1007/BF03033172 Morris, 2003, Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease, Arch Neurol, 60, 940, 10.1001/archneur.60.7.940